Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial)

Heart and Vessels

Volumn 31, Issue 10, 2016, Pages 1583-1589

  Shimomura, Mitsuhiro ^a   Oyama, Jun ichi ^a   Takeuchi, Masayoshi ^b   Shibata, Yoshisato ^c   Yamamoto, Yusuke ^d   Kawasaki, Tomohiro ^e   Komoda, Hiroshi ^a   Kodama, Kazuhisa ^a   Sakuma, Masashi ^a   Toyoda, Shigeru ^f   Inoue, Yohei ^c   Mine, Daigo ^a   Natsuaki, Masahiro ^d   Komatsu, Aiko ^a   Hikichi, Yutaka ^a   Yamagishi, Sho ichi ^g   Inoue, Teruo ^f   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c Miyazaki Medical Association Hospital   (Japan)

^d SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^e Shin Koga Hospital   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myocardial infarction; Inflammation; Oxidative stress; Statin

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOPOIETIN LIKE PROTEIN 2; ATORVASTATIN; BIOLOGICAL MARKER; GLYCERALDEHYDE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TOXIC ADVANCED GLYCATION END PRODUCT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANGIOPOIETIN; ANGPTL2 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEART DISEASE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HOSPITAL ADMISSION; HUMAN; JAPAN; MAJOR ADVERSE CARDIAC AND CEREBROVASCULAR EVENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ACUTE DISEASE; AGED; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANGIOPOIETINS; ATORVASTATIN CALCIUM; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84951793287     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-015-0773-y     Document Type: Article

References (30)

1. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Takeshita A (2002) Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105:868–873
2. Wright DG, Lefer DJ (2005) Statin mediated protection of ischemic myocardium. Vascul Pharmacol 42:265–270
3. Malik S, Sharma AK, Bharti S, Nepal S, Bhatia J, Nag TC, Narang R, Arya DS (2011) In vivo cardioprotection by pitavastatin from ischemic-reperfusion injury through suppression of IKK/NF-κB and upregulation of pAkt-e-NOS. J Cardiovasc Pharmacol 58:199–206
4. Vilahur G, Casani L, Peria E, Juan-Babot O, Mendiata G, Crespo J, Badimon L (2014) HMG-CoA reductase inhibition prior reperfusion improve reparative fibrosis post-myocardial infarction in a preclinical experimental model. Int J Cardiol 175:528–538
5. Kurisu S, Ishibashi K, Kato Y, Mitsuba N, Dohi Y, Nishioka K, Kihara Y (2013) Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease. Heart Vessels 28:34–38
6. Kaneko H, Yajima J, Oikawa Y, Tanaka S, Fukamachi D, Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Kano H, Uejima T, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita T (2014) Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart Vessels 29:21–28
7. Okumura S, Sakakibara M, Hayashida R, Jinno Y, Tanaka A, Okada K, Hayashi M, Ishii H, Murohara T (2014) Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio. Heart Vessels 29:7–14
8. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Investigators (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndrome: phase Z of the A to Z trial. JAMA 292:1307–1316
9. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Glugliano RP, Cairns R, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction-22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495–1504
10. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD (2002) Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105:1446–1452
11. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized control trial. JAMA 294:2437–2445
12. Lenderink T, Boersma E, Gitt AK, Zeymer U, Wallentin L, Van de Werf F, Hasdai D, Behar S, Simoons ML (2006) Patients using statin treatment within 24H after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J 27:1799–1804
13. Zhou Z, Rahme E, Pilote L (2006) Association between time of statin initiation after hospital discharge from acute myocardial infarction and risk of recurrence and mortality in patients > or =65 years of age. Am J Cardiol 97:155–159
14. Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, McGuire DK, Moliterno DJ, Verheugt FW, Weaver WD, Califf RM, SYMPHONY and 2nd SYMPHONY Investigator (2002) Sibrafiban vs aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 287:3087–3095
15. Li YH, Wu HL, Yang YH, Tsai HS, Chao TH (2007) Effect of early versus late in-hospital initiation of statin therapy on the clinical outcomes of patients with acute coronary syndrome. Int Heart J 48:677–688
16. Nakamura I, Oyama J, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, Hiwatashi A, Komatsu A, Takeuchi M, Yamagishi S, Inoue T, Node K (2014) Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovasc Diabetol 13:15
17. Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K (2008) Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 124:319–325
18. Komoda H, Inoue T, Node K (2010) Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens 32:121–128
19. Oike Y, Tabata M (2009) Angiopoietin-like proteins–potential therapeutic targets for metabolic syndrome and cardiovascular disease. Circ J 73:2192–2197
20. Doi Y, Ninomiya T, Hirakawa Y, Takahashi O, Mukai N, Hata J, Iwase M, Kitazono T, Oike Y, Kiyohara Y (2013) Angiopoietin-like protein 2 and risk of type 2 diabetes in a general Japanese population: the Hisayama study. Diabetes Care 36:98–100
21. Usui T, Ninomiya T, Nagata M, Takahashi O, Doi Y, Hata J, Fukuhara M, Kitazono T, Oike Y, Kiyohara Y (2013) Angiopoietin-like protein 2 is associated with chronic kidney disease in a general Japanese population: the Hisayama Study. Circ J 77:2311–2317
22. Huang CL, Wu YW, Wu CC, Hwang JJ, Yang WS (2015) Serum angiopoietin-like protein 2 concentrations are independently associated with heart failure. PLoS One 10:e0138678
23. Higashi Y, Noma K, Yoshizumi M, Kihara Y (2009) Endothelial function and oxidative stress in cardiovascular diseases. Circ J 73:411–418
24. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE (2006) Diabetes and advanced glycoxidation end products. Diabetes Care 29:1420–1432
25. Takeuchi M, Yamagishi S (2004) TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses 63:449–452
26. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M (2006) TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 6:351–358
27. Takeuchi M, Takino J, Yamagishi S (2010) Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. Curr Drug Targets 11:1468–1482
28. Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM (2008) Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci 1126:7–13
29. Del Turco S, Basta G (2012) An update on advanced glycation endproducts and atherosclerosis. Biofactors 38:266–274
30. Jain MK, Ridker PM (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4:977–987